Advanced therapeutic strategies for HBV-related acute-on-chronic liver failure
Xin-Yu Liu, Feng Peng, Ya-Jie Pan and Jun Chen
Changsha, China
Author Affiliations: Liver Diseases Center, Second Xiangya Hospital, Central South University, Changsha 410011, China (Liu XY, Peng F, Pan YJ and Chen J); Department of Infectious Diseases, Third Xiangya Hospital, Central South University, Changsha 410013, China (Liu XY)
Corresponding Author: Jun Chen, MD, PhD, Liver Diseases Center, Second Xiangya Hospital, Central South University, Changsha 410011, China (Tel/Fax: +86-731-85292105; Email: drchenjun@163.com)
BACKGROUND: Acute-on-chronic liver failure (ACLF) is increasingly recognized as a distinct clinical entity and is associated with a high short-term mortality. The most common cause of ACLF is chronic hepatitis B worldwide. Currently, there is no standardized approach for the management of ACLF and the efficacy and safety of therapeutic modalities are uncertain.
DATA SOURCES: PubMed and Web of Science were searched for English-language articles. The search criteria focused on clinical trials and observational studies on the treatment of patients with HBV-related ACLF.
RESULTS: Therapeutic approaches for ACLF in patients with chronic hepatitis B included nucleos(t)ide analogues, artificial liver support systems, immune regulatory therapy, stem cell therapy and liver transplantation. All of these therapeutic approaches have shown the potential to improve liver function and increase patients' survival rate, but most of the studies were not randomized or controlled.
CONCLUSION: Substantial challenges for the treatment of HBV-related ACLF remain and further basic research and randomized controlled clinical trials are needed.
2015, Vol. 14 
